Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
Industry body aims to strengthen policy advocacy, innovation, and global competitiveness of India's fast-growing CRDMO sector
Juneja brings more than three decades of experience in pharmaceutical sales and marketing
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
